Event Date/Time: Apr 18, 2012
End Date/Time: Apr 19, 2012
The newest therapies in more than a decade for people infected with the Hepatitis C virus (HCV) have recently hit the market. Hear about the chemistry of this new class of protease inhibitors and progress on 2nd generation versions, as well as updates on the clinical progress and chemical optimizations of other direct acting antivirals (DAAs). An emphasis will be on progress of various combinations of the new DAAs, especially in the context of an ideal interferon-free regimen. Newer anti-HCV drug candidates, including those that target host/virus interactions will also be covered.